LEADER 02258nam  2200553   450 
001 9910792287003321
005 20230803024232.0
010   $a1-78084-315-1
035   $a(CKB)2560000000152106
035   $a(EBL)1179633
035   $a(SSID)ssj0001526194
035   $a(PQKBManifestationID)11887088
035   $a(PQKBTitleCode)TC0001526194
035   $a(PQKBWorkID)11504457
035   $a(PQKB)10540034
035   $a(MiAaPQ)EBC1179633
035   $a(Au-PeEL)EBL1179633
035   $a(OCoLC)877766976
035   $a(EXLCZ)992560000000152106
100   $a20220517d2013      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aClostridium difficile $enew challenges for an old foe /$feditors, Glenn S. Tillotson, Karl Weiss
205   $a1st ed.
210  1$aLondon, England :$cFuture Medicine Ltd.,$d[2013]
210  4$dİ2013
215   $a1 online resource (157 p.)
300   $aDescription based upon print version of record.
311   $a1-78084-317-8 
327   $aTitle page; Copyright page; Contents; Foreword. Clostridium difficile: new challenges for an old foe; 1. Clostridium difficile infection: a global threat; 2. Pathogenicity mechanisms of Clostridium difficile; 3. Immunology and Clostridium difficile; 4. The microbiome and Clostridium difficile infection; 5. Economic burden of Clostridium difficile infection; 6. Laboratory diagnosis of Clostridium difficile infection; 7. Conventional therapeutics for Clostridium difficile infection; 8. Infection control issues in Clostridium difficile
327   $a9. Future and alternative approaches to managing Clostridium difficile infectionEpilogue. Recent advances with Clostridium difficile; Index
330   $aClostridium Difficile: New Challenges for an Old Foe
606   $aClostridium difficile
606   $aClostridium diseases
615  0$aClostridium difficile.
615  0$aClostridium diseases.
676   $a616.3447
702   $aWeiss$b Karl
702   $aTillotson$b Glenn S.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910792287003321
996   $aClostridium difficile$92650510
997   $aUNINA